Vaccine Strategies against Human Papillomavirus: A Discussion Focused on Developing Countries

  • de Freitas A
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Cervical cancer is the second most common form of cancer among women, and responsible for 274,000 deaths each year, most of which occur in developing countries. Persistent infection with high-risk human papillomavirus (HR-HPV) is an essential factor in the development of cervical cancer and also a contributory factor in other types of cancer. The current prophylactic HPV vaccines provide protection against the -16 and -18 genotypes which are most commonly associated with cervical cancer worldwide. However, the increased costs of these vaccines inhibit their implementation in developing countries, affecting their viability. Moreover, a therapeutic vaccine is needed for women who are already infected by HPV and/or affected by HPV-related cancer. A number of innovative approaches to combat and treat HPV infection are currently being studied and some of these will be consider in this work, together with the development of new vaccines, especially in seriously affected areas located in developing countries. At the same time, there will be a discussion of the issues involved in carrying out effective HPV vaccination programs; these will take account of financial constraints, the lack of adequate infrastructure and the competing priorities, that are found in the surrounding social context of the developing countries.

Cite

CITATION STYLE

APA

de Freitas, A. C. (2012). Vaccine Strategies against Human Papillomavirus: A Discussion Focused on Developing Countries. Journal of Clinical & Cellular Immunology, 01(S4). https://doi.org/10.4172/2155-9899.s4-004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free